Growth-stimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells

Molecular and Cellular Endocrinology

Volumn 190, Issue 1-2, 2002, Pages 65-73

  Barsalou, Annie ^a   Dayanl, Guila ^a   Anghel, Silvia I ^a   Alaoui Jamali, Moulay ^b,c   Van De Veldel, Patrick ^d   Mader, Sylvie ^a,c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d SANOFI   (France)

Author keywords

Antiestrogens; Endometrial carcinoma; Estrogen receptor; Raloxifene; Tamoxifen

Indexed keywords

11 [4 (2 DIMETHYLAMINOETHOXY)PHENYL]ESTRADIOL; 11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 4 HYDROXYTAMOXIFEN; ESTRADIOL; FULVESTRANT; ICI 82780; PROGESTERONE; PROGESTERONE RECEPTOR; RALOXIFENE; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; ANTIESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENDOMETRIUM CELL; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; REPORTER GENE; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; CANCER TRANSPLANTATION; CELL DIVISION; CELL LINE; CELL TRANSPLANTATION; CYTOLOGY; DNA RESPONSIVE ELEMENT; ENDOMETRIUM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PROMOTER REGION; RANDOMIZATION;

ANIMALS; CELL DEATH; CELL DIVISION; CELL LINE; CELL TRANSPLANTATION; ENDOMETRIUM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIECTOMY; PROGESTERONE; PROMOTER REGIONS (GENETICS); RALOXIFENE; RANDOM ALLOCATION; RESPONSE ELEMENTS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRANSCRIPTION, GENETIC;

EID: 0037171445     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(02)00011-4     Document Type: Article

References (38)

1. Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line)
2. Estrogen response elements can mediate agonist activity of anti-estrogens in human endometrial Ishikawa cells
3. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen
4. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
5. Molecular basis of agonism and antagonism in the oestrogen receptor
6. Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse
7. From adjuvant therapy to breast cancer prevention: Bcpt and star
8. Rapid activation of MAP kinase by estrogen in the bone cell line
9. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
10. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
11. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex
12. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse
13. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice
14. Molecular determinants of tissue selectivity in estrogen receptor modulators
15. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells
16. The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa)
17. Antiestrogen therapy for breast cancer: Current strategies and future prospects
18. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B
19. Antiestrogens: Mechanisms and actions in target cells
20. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
21. Estrogen receptor pathways and AP-1
22. Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells
23. Basic guide to the mechanisms of antiestrogen action
24. A steroid-inducible promoter for the controlled overexpression of cloned genes in eukaryotic cells
25. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells
26. Tamoxifen to raloxifene and beyond
27. The case for clinical trials of tamoxifen for prevention of breast cancer
28. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
29. Raloxifene, tamoxifene, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats
30. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
31. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells
32. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer
33. Risk of endometrial cancer after tamoxifen treatment of breast cancer
34. Breast Cancer Prevention Study aims to overcome drug bias
35. Unique protein determinants of the subtype-selective ligand responses of the estrogen receptors (ERα and ERβ) at AP-1 sites
36. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
37. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions
38. A simple and sensitive high-throughput assay for steroid agonists and antagonists